Humacyte Q1 net loss $31.9M; FDA grants Priority Review for HAV, PDUFA Aug 10, 2024

Humacyte, Inc.

2024-Q1 EPS reported -$0.29

Net loss $31.9M vs $37.0M YoY; no revenue; cash $115.5M, up from $35.1M net provided.
BLA for HAV in vascular trauma accepted with Priority Review; PDUFA date Aug 10, 2024.
Raised ~$43M net from public offering in March 2024; additional $20M draw from Oberland facility.
Total operating expenses $26.6M flat QoQ; R&D $21.3M up from $17.3M YoY.
Preparations for US launch ongoing: hired VP Sales, completed Budget Impact Model, seeking ICD-10 code.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Humacyte, Inc. reported financial results for first quarter ended March 31, 2024.

Period: first quarter ended March 31, 2024
Result: reported results

Exact text from the filing

On May 10, 2024, Humacyte, Inc. issued a press release regarding its financial results for its fiscal first quarter ended March 31, 2024.

View on SEC.gov

1436 earnings releases filed in the last 30 days. Browse all earnings releases →

Humacyte, Inc. filing history →

Source: SEC EDGAR

accession 0001818382-24-000054

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.